ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
ALX Oncology (NASDAQ: ALXO), a clinical-stage biotechnology company focused on developing cancer therapies, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.
The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access the event through a webcast or by dialing 1-877-407-0752 (US) or +1-201-389-0912 (International). Presentation slides and an archived recording will be available on the company's website.
ALX Oncology (NASDAQ: ALXO), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie oncologiche, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 12 agosto 2025, dopo la chiusura del mercato.
La societ脿 terr脿 una conference call e una trasmissione web alle 13:30 PT / 16:30 ET dello stesso giorno. Gli investitori potranno partecipare all'evento tramite webcast o chiamando il numero 1-877-407-0752 (USA) o +1-201-389-0912 (Internazionale). Le slide della presentazione e la registrazione archiviata saranno disponibili sul sito web della societ脿.
ALX Oncology (NASDAQ: ALXO), una empresa biotecnol贸gica en etapa cl铆nica enfocada en el desarrollo de terapias contra el c谩ncer, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 12 de agosto de 2025, despu茅s del cierre del mercado.
La compa帽铆a realizar谩 una llamada de conferencia y una transmisi贸n en l铆nea a las 1:30 PM PT / 4:30 PM ET del mismo d铆a. Los inversores podr谩n acceder al evento a trav茅s de la transmisi贸n web o llamando al 1-877-407-0752 (EE.UU.) o +1-201-389-0912 (Internacional). Las diapositivas de la presentaci贸n y una grabaci贸n archivada estar谩n disponibles en el sitio web de la empresa.
ALX Oncology (NASDAQ: ALXO)電� 鞎� 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 2025雲� 2攵勱赴 鞛 鞁れ爜 氚滍憸毳� 2025雲� 8鞗� 12鞚� 鞁滌灔 毵堦皭 頉勳棎 鞓堨爼頃橁碃 鞛堨姷雼堧嫟.
須岇偓電� 臧欖潃 雮� 鞓ろ泟 1鞁� 30攵� PT / 鞓ろ泟 4鞁� 30攵� ET鞐� 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� 鞗轨簮鞀ろ姼毳� 韱淀暣 霕愲姅 氙戈淡 雮� 1-877-407-0752, 甑牅 鞝勴檾 +1-201-389-0912搿� 鞝勴檾頃橃棳 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 氚滍憸 鞀澕鞚措摐鞕� 雲鬼檾氤胳潃 須岇偓 鞗轨偓鞚错姼鞐愳劀 鞝滉车霅╇媹雼�.
ALX Oncology (NASDAQ : ALXO), une entreprise biotechnologique en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies contre le cancer, a pr茅vu l鈥檃nnonce des r茅sultats financiers du deuxi猫me trimestre 2025 pour le 12 ao没t 2025, apr猫s la cl么ture du march茅.
La soci茅t茅 organisera une conf茅rence t茅l茅phonique et un webinaire 脿 13h30 PT / 16h30 ET le m锚me jour. Les investisseurs pourront acc茅der 脿 l鈥櫭﹙茅nement via un webinaire ou en appelant le 1-877-407-0752 (脡tats-Unis) ou le +1-201-389-0912 (International). Les diapositives de la pr茅sentation ainsi qu鈥檜n enregistrement archiv茅s seront disponibles sur le site internet de la soci茅t茅.
ALX Oncology (NASDAQ: ALXO), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Krebstherapien spezialisiert hat, hat die Ver枚ffentlichung der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r den 12. August 2025 nach B枚rsenschluss geplant.
Das Unternehmen wird am selben Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten. Investoren k枚nnen 眉ber einen Webcast teilnehmen oder unter der Nummer 1-877-407-0752 (USA) bzw. +1-201-389-0912 (international) anrufen. Pr盲sentationsfolien und eine Archivaufnahme werden auf der Website des Unternehmens verf眉gbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients鈥� lives, today announced plans to report its second quarter 2025 financial results and a business update on Tuesday, August 12th, 2025, after market close. The company will be hosting a teleconference in conjunction with its financial results press release.
Second Quarter 2025 Webcast Information
Date & Time: Tuesday, August 12, 2025 at 1:30pm PT / 4:30pm ET
Webcast Access:
Participant Listening Options by Phone: To access the conference call, please dial 1-877- 407-0752 or +1-201-389-0912 and ask to be joined into the ALX Oncology Second Quarter 2025 Financial Results Conference Call.
Another option for instant telephone access to the event is to use the Call me鈩� link below:
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, . An archived webcast will be available on the Company's website after the event.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients鈥� lives. ALX Oncology鈥檚 lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology鈥檚 second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at聽聽and on LinkedIn聽.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
Media Contact:
Audra Friis, Sam Brown Healthcare Communications
(917) 519-9577
FAQ
When will ALX Oncology (ALXO) report Q2 2025 earnings?
How can investors access ALX Oncology's Q2 2025 earnings call?
What time is ALX Oncology's Q2 2025 earnings call?
Where can I find ALX Oncology's Q2 2025 earnings presentation materials?
